RosettaSX: Reliable gene expression signature scoring of cancer models and patients.


Journal

Neoplasia (New York, N.Y.)
ISSN: 1476-5586
Titre abrégé: Neoplasia
Pays: United States
ID NLM: 100886622

Informations de publication

Date de publication:
11 2021
Historique:
received: 11 06 2021
revised: 28 08 2021
accepted: 30 08 2021
pubmed: 29 9 2021
medline: 8 2 2022
entrez: 28 9 2021
Statut: ppublish

Résumé

Gene expression signatures have proven their potential to characterize important cancer phenomena like oncogenic signaling pathway activities, cellular origins of tumors, or immune cell infiltration into tumor tissues. Large collections of expression signatures provide the basis for their application to data sets, but the applicability of each signature in a new experimental context must be reassessed. We apply a methodology that utilizes the previously developed concept of coherent expression of genes in signatures to identify translatable signatures before scoring their activity in single tumors. We present a web interface (www.rosettasx.com) that applies our methodology to expression data from the Cancer Cell Line Encyclopaedia and The Cancer Genome Atlas. Configurable heat maps visualize per-cancer signature scores for 293 hand-curated literature-derived gene sets representing a wide range of cancer-relevant transcriptional modules and phenomena. The platform allows users to complement heatmaps of signature scores with molecular information on SNVs, CNVs, gene expression, gene dependency, and protein abundance or to analyze own signatures. Clustered heatmaps and further plots to drill-down results support users in studying oncological processes in cancer subtypes, thereby providing a rich resource to explore how mechanisms of cancer interact with each other as demonstrated by exemplary analyses of 2 cancer types.

Identifiants

pubmed: 34583245
pii: S1476-5586(21)00075-0
doi: 10.1016/j.neo.2021.08.005
pmc: PMC8479477
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1069-1077

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Références

NPJ Breast Cancer. 2018 Jun 25;4:13
pubmed: 29951581
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Br J Cancer. 2012 Jan 3;106(1):126-32
pubmed: 22095227
Front Oncol. 2020 Jan 10;9:1497
pubmed: 31998649
Breast Cancer Res Treat. 2019 Apr;174(3):649-659
pubmed: 30610490
Clin Cancer Res. 2012 May 1;18(9):2695-703
pubmed: 22351685
Nat Genet. 2017 Dec;49(12):1779-1784
pubmed: 29083409
Nat Methods. 2016 Mar;13(3):241-4
pubmed: 26780092
Oncogene. 2007 Jan 11;26(2):312-20
pubmed: 16819509
Nat Commun. 2020 Apr 14;11(1):1787
pubmed: 32286297
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Int J Genomics. 2017;2017:2354564
pubmed: 28265563
Mol Endocrinol. 2011 Feb;25(2):199-211
pubmed: 20861225
Nat Genet. 2004 Oct;36(10):1090-8
pubmed: 15448693
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
Oncogene. 2005 Jul 7;24(29):4660-71
pubmed: 15897907
J Clin Oncol. 2014 Sep 1;32(25):2794-803
pubmed: 25049332
Mod Pathol. 2014 Apr;27(4):554-61
pubmed: 24051696
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5
pubmed: 16141321
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nat Rev Immunol. 2015 Mar;15(3):172-84
pubmed: 25712152
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Oncol Lett. 2016 Dec;12(6):4869-4876
pubmed: 28105194
Transl Oncol. 2012 Aug;5(4):297-304
pubmed: 22937182
Nat Biotechnol. 2020 Jun;38(6):669-673
pubmed: 32444852
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
J Pathol. 2013 Sep;231(1):63-76
pubmed: 23836465
Genome Biol. 2015 Mar 31;16:64
pubmed: 25853550
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Curr Mol Med. 2012 Jan;12(1):96-110
pubmed: 22082486
Stat Appl Genet Mol Biol. 2004;3:Article16
pubmed: 16646794
Pathology. 2020 Jan;52(1):53-67
pubmed: 31735345
Nat Rev Cancer. 2006 Sep;6(9):735-41
pubmed: 16915294
Oncogene. 2021 Apr;40(15):2651-2666
pubmed: 33692466
BMC Cancer. 2006 Dec 06;6:276
pubmed: 17150101
Breast Cancer Res. 2006;8(4):R34
pubmed: 16846532
PLoS Comput Biol. 2011 Oct;7(10):e1002240
pubmed: 22028643
Nat Protoc. 2019 May;14(5):1377-1400
pubmed: 30971781
Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54
pubmed: 20713713
Ann Oncol. 2014 Feb;25(2):339-45
pubmed: 24347518
Nat Rev Cancer. 2014 Aug;14(8):517-34
pubmed: 25008267
BMC Res Notes. 2019 Sep 23;12(1):605
pubmed: 31547858
Cancer Res. 2009 May 1;69(9):4027-35
pubmed: 19383916
Drug Discov Today. 2018 Nov;23(11):1818-1823
pubmed: 29864526
Sci Rep. 2019 May 21;9(1):7665
pubmed: 31113981
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Science. 2006 Sep 29;313(5795):1929-35
pubmed: 17008526

Auteurs

Julian Kreis (J)

Department of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany; Faculty of Bioscience, University of Heidelberg, Heidelberg, Germany.

Boro Nedić (B)

Department of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany.

Johanna Mazur (J)

Department of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany.

Miriam Urban (M)

Department of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany.

Sven-Eric Schelhorn (SE)

Department of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany.

Thomas Grombacher (T)

Department of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany.

Felix Geist (F)

Therapeutic Innovation Platform Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany.

Benedikt Brors (B)

Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Core Center, Heidelberg, Germany.

Michael Zühlsdorf (M)

Therapeutic Innovation Platform Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany.

Eike Staub (E)

Department of Translational Medicine, Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany. Electronic address: eike.staub@merckgroup.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH